semaglutide cardiovascular outcomes 2025 news today align more closely with attained dose than achieved weight loss Cardiovascular Outcomes in Diabetes: New

It is worth noting that anxiety about treatment , concerns about side effects, or the psychological adjustment to a new medication regimen can independently contribute to sleep difficulties

These drugs are part of a class of medications known as glucagon-like peptide-1 receptor agonists (GLP-1 receptor agonists or GLP-1 RAs)

Note: The above content is only for educational purposes and does not guarantee anything

Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J

Sharon Osbourne In early 2026, KFF reported that up to 60% of older adults taking GLP-1s may stop using them within a year